公开(公告)号：US20240358831A1

公开(公告)日：2024-10-31

申请号：US18685736

申请日：2022-08-24

Applicant: IMMATICS US, INC. ,  Immatics Biotechnologies GmbH

Inventor： Stefanie SPALT ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Steffen WALTER

IPC: A61K39/00 ,  C07K14/74 ,  C12N5/0783

CPC classification number: A61K39/4632 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N2502/11

Abstract: The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.

公开(公告)号：US12123013B2

公开(公告)日：2024-10-22

申请号：US18501269

申请日：2023-11-03

Applicant: Immatics US, Inc.

Inventor： Melinda Mata ,  Mamta Kalra ,  Yannick Bulliard ,  Steffen Walter ,  Ali Mohamed

IPC: C12N15/86 ,  A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/113

CPC classification number: C12N15/86 ,  A61K39/4611 ,  A61K39/4632 ,  A61K39/464499 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/102 ,  C12N15/113 ,  A61K2239/26 ,  C12N2830/48

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

公开(公告)号：US20240150790A1

公开(公告)日：2024-05-09

申请号：US18501269

申请日：2023-11-03

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Yannick BULLIARD ,  Steffen WALTER ,  Ali MOHAMED

IPC: C12N15/86 ,  C07K14/725 ,  C12N15/10 ,  C12N15/113

CPC classification number: C12N15/86 ,  C07K14/7051 ,  C12N15/102 ,  C12N15/113 ,  C12N2830/48

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

公开(公告)号：US11851673B2

公开(公告)日：2023-12-26

申请号：US17197927

申请日：2021-03-10

Applicant: Immatics US, Inc.

Inventor： Melinda Mata ,  Mamta Kalra ,  Yannick Bulliard ,  Steffen Walter ,  Ali Mohamed

IPC: C12N15/86 ,  C07K14/725 ,  C12N15/10 ,  C12N15/113

CPC classification number: C12N15/86 ,  C07K14/7051 ,  C12N15/102 ,  C12N15/113 ,  C12N2830/48

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

公开(公告)号：US20230355678A1

公开(公告)日：2023-11-09

申请号：US18312144

申请日：2023-05-04

Applicant: IMMATICS US, INC.

Inventor： Pooja MEHTA ,  Rene TAVERA ,  Christopher LANIER ,  Mamta KALRA

IPC: A61K35/17 ,  C12N5/0783

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C12N2501/999

Abstract: Methods of manufacturing T cells to improve their efficacy, persistence, memory function, and/or antigen stimulated survival are provided. Methods of manufacturing T cells to improve production of Central Memory T (Tcm) cells are provided. Methods may include culturing or treating T cells with one or more histone deacetylase inhibitor (HDACi) and interleukin-21 (IL-21), with one or more kinase inhibitor, such a tyrosine kinase inhibitor, and/or with one or more AKT inhibitor (AKTi).

公开(公告)号：US20230348561A1

公开(公告)日：2023-11-02

申请号：US18309062

申请日：2023-04-28

Applicant: IMMATICS US, INC.

Inventor： Erik FARRAR ,  Justin GUNESCH ,  Melinda MATA ,  Mohammad HOSSAIN ,  Mamta KALRA ,  Gagan BAJWA

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/63 ,  A61P37/04

CPC classification number: C07K14/7051 ,  C07K14/70517 ,  C12N15/63 ,  A61P37/04

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with dominant negative TGFβ Receptor (“dnTGFβR”) polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for dnTGFβR polypeptides, vectors, and associated methods thereof. The present disclosure further provides for modified CD8 polypeptides, vectors, and associated methods of making and using the same.

公开(公告)号：US11464800B2

公开(公告)日：2022-10-11

申请号：US16271393

申请日：2019-02-08

Applicant: Immatics US, Inc.

Inventor： Mamta Kalra ,  Zoe Coughlin ,  Amir Alpert ,  Steffen Walter ,  Ali Mohamed ,  Agathe Bourgogne

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C12N15/86 ,  A61P31/00 ,  A61P35/00

Abstract: The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.

公开(公告)号：US20220280564A1

公开(公告)日：2022-09-08

申请号：US17281095

申请日：2021-02-23

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Ali MOHAMED ,  Steffen WALTER ,  Yannick BULLIARD

IPC: A61K35/17 ,  C07K14/725 ,  C12N5/0783

Abstract: An in vitro method of expanding γδ T cells includes isolating γδ T cells from a blood sample of a human subject, activating the isolated γδ T cells in the presence of an aminobisphosphonate and/or a feeder cell and at least one cytokine, expanding the activated γδ T cells, and optionally restimulating the expanded γδ T cells.

公开(公告)号：US20210041454A1

公开(公告)日：2021-02-11

申请号：US16988290

申请日：2020-08-07

Applicant: Immatics US, Inc. ,  Immatics Biotechnologies GmbH

Inventor： Chih-Chiang TSOU ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Julian MUELLER

IPC: G01N33/68 ,  G01N30/88

Abstract: The present disclosure relates to methods of improved identification of peptides, for example, antigenic peptides. In particular, the present disclosure relates to methods of more accurately identifying human leukocyte antigen (HLA) peptides by utilizing classification systems. The disclosure also provides for utilizing the described methods for the field of personalized cancer therapies, such as adoptive cellular therapy (ACT).

公开(公告)号：US20210017492A1

公开(公告)日：2021-01-21

申请号：US17062170

申请日：2020-10-02

Applicant: Immatics US, Inc.

Inventor： Thorsten DEMBERG

IPC: C12N5/0783 ,  C07K16/28 ,  A61K35/17

Abstract: The present disclosure generally relates to methods of improving T cell homing to organs or tissues by utilizing compounds and compositions, for example, retinoic acid receptor agonists. In an aspect, the disclosure provides for organ-homing engineered T cells for treating diseases, associated compositions, and methods for preparing thereof.